» Articles » PMID: 38791599

Unraveling the Microbiome-Human Body Axis: A Comprehensive Examination of Therapeutic Strategies, Interactions and Implications

Abstract

This review scrutinizes the intricate interplay between the microbiome and the human body, exploring its multifaceted dimensions and far-reaching implications. The human microbiome, comprising diverse microbial communities inhabiting various anatomical niches, is increasingly recognized as a critical determinant of human health and disease. Through an extensive examination of current research, this review elucidates the dynamic interactions between the microbiome and host physiology across multiple organ systems. Key topics include the establishment and maintenance of microbiota diversity, the influence of host factors on microbial composition, and the bidirectional communication pathways between microbiota and host cells. Furthermore, we delve into the functional implications of microbiome dysbiosis in disease states, emphasizing its role in shaping immune responses, metabolic processes, and neurological functions. Additionally, this review discusses emerging therapeutic strategies aimed at modulating the microbiome to restore host-microbe homeostasis and promote health. Microbiota fecal transplantation represents a groundbreaking therapeutic approach in the management of dysbiosis-related diseases, offering a promising avenue for restoring microbial balance within the gut ecosystem. This innovative therapy involves the transfer of fecal microbiota from a healthy donor to an individual suffering from dysbiosis, aiming to replenish beneficial microbial populations and mitigate pathological imbalances. By synthesizing findings from diverse fields, this review offers valuable insights into the complex relationship between the microbiome and the human body, highlighting avenues for future research and clinical interventions.

Citing Articles

Fecal microbiota transplantation for glaucoma; a potential emerging treatment strategy.

Ebrahimi R, Farsi Y, Nejadghaderi S Curr Res Microb Sci. 2024; 7:100314.

PMID: 39726974 PMC: 11670420. DOI: 10.1016/j.crmicr.2024.100314.


Gut microbiota in health and disease: advances and future prospects.

Zhang Y, Wang H, Sang Y, Liu M, Wang Q, Yang H MedComm (2020). 2024; 5(12):e70012.

PMID: 39568773 PMC: 11577303. DOI: 10.1002/mco2.70012.


Lifestyle Medicine and the Microbiome: Holistic Prevention and Treatment.

Manske S Integr Med (Encinitas). 2024; 23(5):10-14.

PMID: 39534661 PMC: 11552958.


Special Issue: "Gut Microbiota and Nutrition in Human Health".

Park S Int J Mol Sci. 2024; 25(21).

PMID: 39519138 PMC: 11546776. DOI: 10.3390/ijms252111589.


A new perspective in intestinal microecology: lifting the veil of exercise regulation of cardiometabolic diseases.

Gao C, Wei J, Lu C, Wang L, Dong D, Sun M Gut Microbes. 2024; 16(1):2404141.

PMID: 39305272 PMC: 11418258. DOI: 10.1080/19490976.2024.2404141.


References
1.
Slavin J . Dietary fiber: classification, chemical analyses, and food sources. J Am Diet Assoc. 1987; 87(9):1164-71. View

2.
Kaufman S, Sanders D, Thomas T, Ruchinskas A, Vaquer-Alicea J, Sharma A . Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo. Neuron. 2016; 92(4):796-812. PMC: 5392364. DOI: 10.1016/j.neuron.2016.09.055. View

3.
Ringel-Kulka T, Cheng J, Ringel Y, Salojarvi J, Carroll I, Palva A . Intestinal microbiota in healthy U.S. young children and adults--a high throughput microarray analysis. PLoS One. 2013; 8(5):e64315. PMC: 3662718. DOI: 10.1371/journal.pone.0064315. View

4.
Finegold S, Downes J, Summanen P . Microbiology of regressive autism. Anaerobe. 2011; 18(2):260-2. DOI: 10.1016/j.anaerobe.2011.12.018. View

5.
Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan G . Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 2017; 318(20):1985-1993. PMC: 5820695. DOI: 10.1001/jama.2017.17077. View